Department for Vascular Surgery, University Hospital Zurich, Zurich, Switzerland.
Department for Vascular Surgery, Inselspital, Bern University Hospital, Bern, Switzerland.
Sci Rep. 2022 Nov 15;12(1):19540. doi: 10.1038/s41598-022-24060-5.
The role of endovascular aneurysm repair (EVAR) in patients with asymptomatic abdominal aortic aneurysm (AAA) who are unfit for open surgical repair has been questioned. The impending risk of aneurysm rupture, the risk of elective repair, and the life expectancy must be balanced when considering elective AAA repair. This retrospective observational cohort study included all consecutive patients treated with standard EVAR for AAA at a referral centre between 2001 and 2020. A previously published predictive model for survival after EVAR in patients treated between 2001 and 2012 was temporally validated using patients treated at the same institution between 2013 and 2020 and updated using the overall cohort. 558 patients (91.2% males, mean age 74.9 years) were included. Older age, lower eGFR, and COPD were independent predictors for impaired survival. A risk score showed good discrimination between four risk groups (Harrel's C = 0.70). The 5-years survival probabilities were only 40% in "high-risk" patients, 68% in "moderate-to-high-risk" patients, 83% in "low-to-moderate-risk", and 89% in "low-risk" patients. Low-risk patients with a favourable life expectancy are likely to benefit from EVAR, while high-risk patients with a short life expectancy may not benefit from EVAR at the current diameter threshold.
腔内动脉瘤修复(EVAR)在不适合开放手术修复的无症状腹主动脉瘤(AAA)患者中的作用受到质疑。在考虑选择性 AAA 修复时,必须平衡动脉瘤破裂的即将发生的风险、择期修复的风险和预期寿命。本回顾性观察队列研究纳入了 2001 年至 2020 年间在一家转诊中心接受标准 EVAR 治疗的所有连续 AAA 患者。使用 2013 年至 2020 年间在同一机构接受治疗的患者对 2001 年至 2012 年间接受治疗的患者进行 EVAR 后生存的预测模型进行了时间验证,并使用整个队列进行了更新。共纳入 558 例患者(91.2%为男性,平均年龄 74.9 岁)。年龄较大、较低的 eGFR 和 COPD 是生存受损的独立预测因素。风险评分显示四个风险组之间具有良好的区分能力(Harrel 的 C=0.70)。“高危”患者的 5 年生存率仅为 40%,“中高危”患者为 68%,“低中危”患者为 83%,“低危”患者为 89%。低危患者如果预期寿命良好,可能会从 EVAR 中获益,而预期寿命较短的高危患者可能不会从目前的直径阈值的 EVAR 中获益。